Literature DB >> 23430488

Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?

Carla Pinto Moura1, Carlos Soares, Daniela Seixas, Margarida Ayres-Bastos, João Paulo Oliveira.   

Abstract

Fabry disease (FD) is caused by progressive accumulation of neutral glycosphingolipids, including in ganglion neural and vascular endothelial cells, as a result of lysosomal α-galactosidase deficiency. High frequencies progressive sensorineural hearing loss (HL), sudden deafness, tinnitus and dizziness are otological symptoms frequently reported.A 45-year-old man with FD, on haemodialysis since age 25, complaining of progressive HL, was started on enzyme replacement therapy (ERT) because of cardiac complications. A bilateral sloping sensorineural HL was found at baseline audiological evaluation. Computed tomography of the ears showed enlargement of the intradiploic vascular channels, principally in the petrous bone. The magnetic resonance angiography showed elongation and ectasia of the middle cerebral arteries and the arteries of the Circle of Willis, particularly the internal carotid and the basilar arteries. Follow-up audiological evaluations documented progressive worsening of HL, mainly in the high frequencies range, despite high dose ERT and evidence of cardiac improvement.The intradiploic vascular abnormalities of the temporal bones reported herein have never been described in association with FD and may have contributed to the pathogenesis of progressive HL, by a 'stealing' effect upon the cochlear blood supply (like in cavernous haemangioma of the internal auditory meatus), in addition to the other mechanisms of ischaemic injury to the Organ of Corti described in FD. This clinical observation shows the value of comprehensive neuroimaging investigation of HL in FD and emphasizes the importance of early institution of specific therapy, before the occurrence of irreversible inner ear lesions and hearing damage.

Entities:  

Year:  2012        PMID: 23430488      PMCID: PMC3575050          DOI: 10.1007/8904_2012_132

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  30 in total

1.  Hearing evaluation with distortion-product otoacoustic emissions in young patients undergoing haemodialysis.

Authors:  P Stavroulaki; T P Nikolopoulos; I Psarommatis; N Apostolopoulos
Journal:  Clin Otolaryngol Allied Sci       Date:  2001-06

2.  A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.

Authors:  Karen Lee; Xiaoying Jin; Kate Zhang; Lorraine Copertino; Laura Andrews; Jennifer Baker-Malcolm; Laura Geagan; Huawei Qiu; Keirsten Seiger; Debra Barngrover; John M McPherson; Tim Edmunds
Journal:  Glycobiology       Date:  2003-01-03       Impact factor: 4.313

Review 3.  Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Authors:  Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

4.  Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy.

Authors:  B Sergi; G Conti; G Paludetti
Journal:  Acta Otorhinolaryngol Ital       Date:  2010-04       Impact factor: 2.124

5.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

6.  Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease.

Authors:  Markus Kosch; Hans-Georg Koch; Joao Paulo Oliveira; Carlos Soares; Francesco Bianco; Frank Breuning; Ase Krogh Rasmussen; Roland M Schaefer
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

7.  Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy.

Authors:  D Hajioff; Y Enever; R Quiney; J Zuckerman; K Mackermot; A Mehta
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Hearing improvement in patients with Fabry disease treated with agalsidase alfa.

Authors:  D Hajioff; S Goodwin; R Quiney; J Zuckerman; K D MacDermot; A Mehta
Journal:  Acta Paediatr Suppl       Date:  2003-12

9.  Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females.

Authors:  G Conti; B Sergi
Journal:  Acta Paediatr Suppl       Date:  2003-12

10.  Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients.

Authors:  Dominique P Germain; Paul Avan; Augustin Chassaing; Pierre Bonfils
Journal:  BMC Med Genet       Date:  2002-10-11       Impact factor: 2.103

View more
  1 in total

Review 1.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Authors:  Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada
Journal:  Mol Genet Metab Rep       Date:  2019-02-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.